Case-Based Roundtable
General Dermatology
Eczema
Chronic Hand Eczema
Chronic Spontaneous Urticaria
Alopecia
Aesthetics
Vitiligo
COVID-19
Actinic Keratosis
Precision Medicine and Biologics
Rare Disease
Wound Care
Rosacea
Psoriasis
Psoriatic Arthritis
Atopic Dermatitis
Melasma
NP and PA
Skin Cancer
Hidradenitis Suppurativa
Drug Watch
Pigmentary Disorders
Acne
Pediatric Dermatology
Practice Management
Prurigo Nodularis
Buy-and-Bill

News

Article

June 9, 2025

Daily Derm Times: June 9, 2025

Author(s):

Emma Andrus, Editor

Key Takeaways

Denifanstat shows promising phase 3 results for acne, indicating potential advancements in acne treatment.
Barzolvolimab, an anti-KIT antibody, rapidly reduces symptoms in antihistamine-refractory chronic spontaneous urticaria.
Almirall pioneers the use of the WHO-5 Well-Being Index in dermatological clinical trials, emphasizing psychological well-being.
Emerging therapies for lichen planus are gaining attention, highlighting ongoing research efforts in dermatology.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

The Rx Recap: June 1-7

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

The Weekly Roundup: June 2-6

In case you missed it, this week we had news about denifanstat's promising phase 3 results for acne, emerging therapies in lichen planus, initial insights from RAD 2025, and more.

Dermatology Times' Weekly Crossword: June 9, 2025

Test your knowledge of key words and terms associated with dermatology news from the previous week.

Barzolvolimab Demonstrates Rapid Symptom Reduction in Chronic Spontaneous Urticaria

The monoclonal anti-KIT antibody exhibited promise in adults with moderate to severe antihistamine–refractory CSU.

Almirall Is First to Apply WHO-5 Well-Being Index in Dermatological Clinical Trial Endpoints

Almirall is pioneering a holistic approach in dermatology, emphasizing psychological well-being through the WHO-5 index in clinical trials.

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe Now!